-
公开(公告)号:CA2631971C
公开(公告)日:2016-10-04
申请号:CA2631971
申请日:2006-12-12
Applicant: ABBOTT LAB
Inventor: DHAON MADHUP , HSIAO CHI-NUNG , PATEL SUBHASH , BONK PETER , CHEMBURKAR SANJAY , CHEN YONG
IPC: C07D498/18 , A61K31/395
Abstract: A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate . After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30~ C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
-
公开(公告)号:NZ568304A
公开(公告)日:2011-07-29
申请号:NZ56830406
申请日:2006-12-12
Applicant: ABBOTT LAB
Inventor: CHEN YONG , DHAON MADHUP , HSIAO CHU-NUNG , PATEL SUBHASH , BONK PETER , CHEMBURKAR SANJAY
IPC: C07D498/18 , A61K31/395
Abstract: Disclosed is a method of preparing a rapamycin derivative zotarolimus molecule of formula I comprising: (a) reacting a molecule of formula II: with triflic anhydride to produce a molecule of the triflate and (b) reacting the molecule of the triflate with a molecule of formula IV: wherein R1 is selected from the group consisting of =O, and (H, OH); R2 and R5 are independently selected from the group consisting of H, -C(=O)R6, -C(=O)OR6, -C(=O) NHR6 and -C(=S)OR6; R3 is selected from the group consisting of =O and OR5; or R2 and R3 can be taken together to form moiety of formula A -C(R7)(R8) -O-B, where A is a bond to oxygen bonded to carbon 28 and B is a bond bonded to carbon 26 as defined above; R4 is selected from the group consisting of H and alkyl; R6 is selected from the group consisting of alkyl, cycloalkyl, aryl groups, and heterocyclic groups; R7 and R8 are independently selected from the group consisting of H, alkyl, or R7 and R8 taken together are =O R9 and R10 are independently selected from the group consisting of H, alkenyl, alkenylcycloalkenyl, alkenylcycloalkyl, alkyl, alkylcycloalkenyl, alkylcycloalkyl, alkynyl, aralkyl, aryl, cycloalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylcycloalkyl, cycloalkenylalkyl, heterocyclyl, and combinations thereof, wherein the reactions are performed in a single pot.
-
公开(公告)号:BG65963B1
公开(公告)日:2010-07-30
申请号:BG10968206
申请日:2006-09-20
Applicant: ABBOTT LAB
Inventor: BAUER JOHN , SALEKI-GERHARDT AZITA , NARAYANAN BIKSHANDARKOIL , CHEMBURKAR SANJAY , PATEL KETAN , SPIWEK HARRY , BAUER PHILIP , ALLEN KIMBERLY
IPC: C07D277/24 , A61K31/425 , A61K31/426 , A61K31/427 , A61P31/18 , A61P37/04 , C07D277/00 , C07D277/28 , C07D277/30 , C07D277/36 , C07D277/40 , C07D277/42 , C07D417/12
Abstract: The invention relates to (2S,3S,5S)-5-{N-[N-(/N-methyl-N-[/2-isopropyl-4-thiazolyl/methyl]amino}carbonyl-L-valinyl)amino]-2-{N-[/5- thiazolyl/methoxycarbonyl]amino}-1,6-diphenyl-3-hydroxyhexane} (ritonavir), in particular to essentially pure amorphous ritonavir, to methods of obtaining it, to pharmaceutical compositions containing it, as well as to a method of obtaining essentially pure crystalline polymorphous forms I and II of ritonavir.
-
公开(公告)号:AT431735T
公开(公告)日:2009-06-15
申请号:AT03777773
申请日:2003-10-22
Applicant: ABBOTT LAB
Inventor: BENNANI YOUSSEF , CHANG SOU-JEN , CHEMBURKAR SANJAY , DART MICHAEL , FERNANADO DILINIE , GRIEME TIMOTHY
IPC: A61K31/19 , A61K31/33 , A61K31/397 , A61K31/401 , A61K31/495 , A61K31/537 , A61K31/54 , A61K31/55 , A61P25/08 , C07C61/13 , C07C61/135 , C07C61/29 , C07C69/753 , C07C233/58 , C07C237/22 , C07C237/24
Abstract: The present invention relates to the use of compounds of formula (I) for the treatment of epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, or movement disorders, and to provide neuroprotection.
-
公开(公告)号:CA2936497A1
公开(公告)日:2007-08-23
申请号:CA2936497
申请日:2006-12-12
Applicant: ABBOTT LAB
Inventor: DHAON MADHUP , HSIAO CHI-NUNG , PATEL SUBHASH , BONK PETER , CHEMBURKAR SANJAY , CHEN YONG
IPC: C07D498/18 , A61K31/436
Abstract: A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate. After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30°C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
-
公开(公告)号:BG65150B1
公开(公告)日:2007-04-30
申请号:BG10519701
申请日:2001-01-30
Applicant: ABBOTT LAB
Inventor: BAUER JOHN , SALEKI-GERHARDT AZITA , NARAYANAN BIKSHANDARKOIL , CHEMBURKAR SANJAY , PATEL KETAN , SPIWEK HARRY , BAUER PHILIP , ALLEN KIMBERLY
IPC: A61K31/426 , A61K31/427 , A61P31/00 , A61P31/18 , A61P37/00 , A61P37/04 , C07D277/00 , C07D277/24 , C07D277/28 , C07D277/30 , C07D277/36 , C07D277/40 , C07D277/42 , C07D417/12
Abstract: The invention relates to a new crystalline polymorphic form of (2S,3S,5S)-5-{N-[N-(/N-methyl-N-[/2-isopropyl-4-thiazolyl/methyl]amino/carbonyl-L-valinyl)amino]-2-{N-/5-thiazolyl/methoxicarbonyl]amino}-1,6-diphenyl-3-xydroxyhexan} (ritonavir), to a method of obtaining it, and to pharmaceutical compositions containing it.
-
公开(公告)号:MY128296A
公开(公告)日:2007-01-31
申请号:MYPI20011034
申请日:2001-03-07
Applicant: ABBOTT LAB
Inventor: DICKMAN DANIEL A , CHEMBURKAR SANJAY , FORT JAMES J , HENRY RODGER F , LECHUGA-BALLESTEROS DAVID , NIU YUPING , PORTER WILLIAM
IPC: C07D239/36 , A61K20060101 , A61K31/513 , A61P20060101 , A61P31/18 , A61P43/00 , C07D20060101 , C07D239/10
Abstract: THERE IS DISCLOSED A NON-SOLVATED CRYSTALLINE FORM OF THE COMPOUND (2S,3S,5S)-2-(2,6 DIMETHYLPHENOXYACETYL)AMINO-3-HYDROXY-5-(2-(1-TETRAHYDRO PYRIMID-2-ONYL)-3-METHYLBUTANOYL)) AMINO-1,6-DIPHENYLHEXANE WITH A PEAK IN THE SOLID STATE INFRARED SPECTRUM AT A POSITION WITHIN THE RANGE 1680-1685 CM¯¹ AND A PEAK IN THE SOLID STATE INFRARED SPECTRUM AT A POSITION WITHIN THE RANGE 1625-1630 CM¯¹.(FIG 1)
-
公开(公告)号:SA1573B1
公开(公告)日:2006-11-14
申请号:SA01220270
申请日:2001-08-07
Applicant: ABBOTT LAB
Inventor: DICKMAN DANIEL A , CHEMBURKAR SANJAY , FORT JAMES J , HENRY RODGER F , LECHUGA-BALLESTEROS DAVID , NIU YUPING , PORTER WILLIAM
IPC: A61K20060101 , A61K31/513 , A61P20060101 , A61P31/18 , A61P43/00 , C07D20060101 , C07D239/10
Abstract: الملخص: يصفالاختراعالراهنأشكالبلورية crystalline forms جديدةمنلوبينافير lopinavir.
-
公开(公告)号:AU2006222711A1
公开(公告)日:2006-10-19
申请号:AU2006222711
申请日:2006-09-27
Applicant: ABBOTT LAB
Inventor: PORTER WILLIAM , FORT JAMES J , NIU YUPING , CHEMBURKAR SANJAY , HENRY RODGER F , LECHUGA-BALLESTEROS DAVID , DICKMAN DANIEL A
IPC: C07D239/10 , A61K20060101 , A61K31/513 , A61P20060101 , A61P31/18 , A61P43/00 , C07D20060101
Abstract: New crystalline forms of lopinavir are disclosed.
-
公开(公告)号:NZ521183A
公开(公告)日:2004-03-26
申请号:NZ52118301
申请日:2001-03-21
Applicant: ABBOTT LAB
Inventor: DICKMAN DANIEL A , CHEMBURKAR SANJAY , FORT JAMES J , ENRY RODGER F , LECHUGA-BALLESTEROS DAVID , NIU YUPING , ORTER WILLIAM
IPC: A61K20060101 , A61K31/513 , A61P20060101 , A61P31/18 , A61P43/00 , C07D20060101 , C07D239/10 , C07D239/00
Abstract: A crystalline hydrated form of lopinavir is disclosed. Such crystalline forms of lopinavir may have a peak in the solid state infrared spectrum at a position within the range 1652 - 1666 cm-1 and a peak in the solid state infrared spectrum at a position within the range 1606-1615 cm-1.
-
-
-
-
-
-
-
-
-